Methylene Blue Market Size & Share, by Application (Aquaculture, Healthcare, Laboratory Research, and Textile Dyeing); Form; Grade; Distribution Channel; and Purity - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 7508
  • Published Date: Apr 15, 2025
  • Report Format: PDF, PPT

 

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Methylene Blue Market size was USD 400 million in 2024 and is estimated to reach USD 1 billion by the end of 2037, expanding at a CAGR of 7.6% during the forecast period, i.e., 2025-2037. In 2025, the industry size of methylene blue is assessed at USD 430 million. 

The methylene blue market is driven by increasing need for healthcare for treating methemoglobinemia, growing use in industrial dyeing processes, and expanding research in neurological and cancer therapies. Furthermore, the environmental concerns and the need for sustainable production methods also influence methylene blue market dynamics, promoting innovations in eco-friendly manufacturing and high-purity formulations. Methylene blue is primarily used to treat methemoglobinemia, a condition characterized by hemoglobin's inability to efficiently release oxygen to the body's tissues. Beyond this, MB serves as an antiseptic and disinfectant and is employed in biological staining and as a redox indicator in analytical chemistry.

In industrial sectors, methylene blue is highly utilized as a dye in textile manufacturing, valued for its vibrant color and strong adherence to fabrics. Additionally, it plays a role in the paper, printing, and painting industries, highlighting its broad utility. Recent studies have revealed new possibilities for the use of MB, particularly in the management of neurodegenerative disorders like Alzheimer’s and Parkinson’s disease.

Studies indicate that MB can improve mitochondrial function, reduce oxidative stress, and inhibit the accumulation of tau proteins, which are associated with Alzheimer’s disease progression. For instance, Nexus Pharmaceuticals, LLC, received U.S. Food and Drug Administration (FDA) approval for its Methylene Blue Injection, USP, in November 2024. This highlights the essential function of MB in the treatment of acquired methemoglobinemia. Sustainability trends are also influencing the methylene blue market. Manufacturers are exploring eco-friendly production methods and sustainable feedstocks to stop the environmental impact associated with MB synthesis.

Additionally, the development of bio-based nanocomposites offers promising solutions for wastewater treatment, utilizing MB removal techniques that are both effective and eco-friendly. These developments underscore methylene blue’s evolving role across multiple sectors, driven by its diverse applications and the continuous pursuit of innovative and sustainable practices.


Methylene Blue Market Size
Get more information on this report: Request Free Sample PDF

Methylene Blue Market: Growth Drivers and Challenges

Growth Drivers

  • Increasing demand for methylene blue in medical applications: MB is a versatile compound with significant applications in the medical field, especially due to its antiseptic properties. It has been effectively utilized in managing urinary tract infections (UTIs) by alleviating discomfort and preventing bacterial growth. Studies demonstrate that a combination of methenamine and methylene blue provided symptomatic relief in patients with recurrent cystitis. Furthermore, MB is the first-line treatment for methemoglobinemia, a condition where hemoglobin’s ability to carry oxygen is impaired. Administered intravenously, MB facilitates the conversion of methemoglobin back to functional hemoglobin, thereby restoring oxygen delivery in the body.

    A significant instance of methylene blue's use in the healthcare industry is its utilization by Provepharm Life Solutions, a pharmaceutical company based in France. Provepharm focuses on providing high-purity methylene blue for medical purposes. This treatment is effective against ProvayBlue, ethylene blue injection, which is FDA-approved for treating methemoglobinemia, a serious blood disorder where hemoglobin is unstable to release oxygen effectively into body tissues. The increasing number of surgical procedures and the rising incidence of hospital-acquired infections have amplified the need for effective antimicrobial agents like methylene blue. Its broad-spectrum efficacy and established safety profile make it an asset in contemporary medical practice.
     
  • Expansion of methylene blue in aquaculture and agriculture: MB is highly utilized in both aquaculture and agriculture for its antifungal and antibacterial properties. In aquaculture, MB is employed to treat fungal infections such as saprolegnia in fish, enhancing the health and productivity of fish farms. For Kordon LLC, the U.S.-based company offers MB, a product particularly formulated to treat fungal infections like saprolegnia in fish. This treatment is effective in combating superficial fungal and bacterial infections and is safe for use with fish eggs and fry, helping to prevent fungal infections.

    Furthermore, in agriculture, MB is used as an antimicrobial agent to protect seeds from soil-borne pathogens. Seed coating with beneficial microbes or antimicrobial compounds has been shown to minimize disease symptoms and promote plant growth. For example, the application of M451 as a seed dressing promotes the growth of wheat seedlings and reduces the presence of root phytopathogenic fungi, without affecting the endophytes. These applications underscore methylene blue’s potential in boosting healthier fish populations and enhancing crop yields through effective disease management strategies.

Challenges

  • Toxicity concerns: The methylene blue market addresses numerous challenges related to toxicity, especially in its expanding use within medical applications. While MB is recognized for its therapeutic efficacy, especially in treating conditions like methemoglobinemia, high doses or improper usage of MB can cause side effects such as serotonin syndrome, particularly when used alongside certain medications. This risk has led to heightened scrutiny from regulatory bodies and necessitates strict monitoring during therapeutic use. The need for careful dosage control and patient evaluation underscores the importance of comprehensive clinical guidelines. As a result, these toxicity-related risks pose limitations on the broader adoption of methylene blue in pharmaceutical treatments and highlight the necessity for further research into safer formulations and delivery methods.
     
  • Environmental impact: The production of methylene blue causes serious environmental impacts. Traditional manufacturing processes often involve the use of hazardous chemicals and generate toxic byproducts, which pose significant risks to ecosystems and public health if not properly managed. Improper disposal or inadequate treatment of chemical waste can lead to soil and water contamination, prompting scrutiny from enviro. For instance, seed dressing and environmental regulatory bodies. As sustainability becomes a key focus across industries, manufacturers are under pressure to adopt cleaner, more eco-friendly production methods. This includes exploring green chemistry approaches, utilizing safer feedstocks, and improving waste treatment systems. Addressing these concerns is critical not only for regulatory compliance but also for ensuring the long-term viability and public acceptance of methylene blue.

Base Year

2024

Forecast Year

2025-2037

CAGR

7.6%

Base Year Market Size (2024)

USD 400 million

Forecast Year Market Size (2037)

USD 1 billion

Regional Scope

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, South Korea, Malaysia, Australia, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Methylene Blue Segmentation

Application (Aquaculture, Healthcare, Laboratory Research, and Textile Dyeing)

Healthcare segment is set to hold methylene blue market share of more than 44.6% by 2037. This dominance is driven by the increasing prevalence of communicable diseases, the complexity of diagnostic procedures, and the widespread use of methylene blue in wound care and surgical applications. Furthermore, methylene blue is employed as a staining agent in several diagnostic procedures, aiding in the visualization of cellular structures during surgeries and laboratory analyses. Its role extends to potential applications in neurogenerative disease research, where studies suggest it may improve cognitive function and reduce amyloid plaques associated with conditions like Alzheimer’s disease.

For instance, Mblue Lab, a woman and minority-owned company in Maryland, has pioneered the usage of methylene blue in skincare through its brand Bluelene.  Founded by Dr. KanCao, a professor of cellular biology at the University of Maryland, Mblue Lab has developed a patented line of anti-aging skincare products that harness the antioxidant properties of methylene blue. Their formulation aims to improve skin health by promoting collagen and elastin production, thereby improving skin elasticity and reducing signs of aging. This innovative approach underscores methylene blue’s potential in enhancing skin therapeutics.

In aquaculture, the growth is attributed to methylene blue’s efficacy in treating and preventing fish diseases, aligning with the adoption of sustainable aquaculture practices. In textile dyeing, MB is used to impart blue coloration to various fabrics. The increasing need for textiles in industries like fashion, automotive, and home furnishing supports this growth. Other applications, including water purification, food additives, and photography, are projected to experience steady growth, driven by the expanding demand for methylene blue across diverse sectors.

Form (Liquid, Powder, and Crystals) 

The liquid segment is projected to hold a substantial share in the global methylene blue market due to its extensive applications in medicine, industry, and research. Its aqueous solution facilities precise dosing and rapid absorption, making it ideal for intravenous treatments of conditions like methemoglobinemia. In industrial settings, liquid methylene blue is preferred for its ease of integration into manufacturing processes, such as textile dyeing. Whereas in laboratory research, there is a significant uptick in the use of liquid methylene blue in research fields such as cell biology, microbiology, and drug discovery, contributing to substantial revenue generation in this segment. For instance, Macsen Laboratories offers high-purity pharmaceutical-grade methylene blue solutions tailored for medical applications, adhering to strict quality standards to ensure high purity, safety, efficacy, and regulatory compliance with stringent quality standards, making the suitable for critical medical applications such as surgeries, and treatment of conditions like methemoglobinemia. This commitment to excellence has positioned the company as a trusted supplier in the pharmaceutical and medical sectors.

Our in-depth analysis of the global methylene blue market includes the following segments:

Application

  • Aquaculture
  • Healthcare
  • Laboratory Research
  • Textile Dyeing
  • Others 

Form
 

  • Liquid
  • Powder
  • Crystals 
     

Grade
 

  • Reagent Grade
  • Technical Grade
  • Food Grade 

Distribution Channel
 

  • Direct Sales
  • Distributors
  • Online Platforms 

Purity
 

  • 90-95%
  • 96-100% 

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Methylene Blue Industry - Regional Synopsis

North America Market Statistics

North America’s methylene blue market is projected to capture revenue share of over 37.2% by 2037. This substantial share is primarily driven by the U.S and Canada, where the compound’s applications in pharmaceuticals, aquaculture, and biological research are extensive. In the U.S., methylene blue is broadly used in medical treatments, notably for conditions like methemoglobinemia, and serves as a vital staining agent in diagnostic procedures. Similarly, Canada’s robust healthcare infrastructure supports significant use of methylene blue in various medical and research applications. Notable companies such as Bio-Rad Laboratories and Canada Wide Scientific are key players in this methylene blue market, contributing to the region’s dominance. For instance, Bio-Rad provides Liquicheck Reticulocyte Control, an assayed, human whole blood control designed to monitor reticulocyte counting using Beckman Coulter VCS instruments and New Methylene Blue stain. This control is available at multiple levels to ensure accuracy in hematology testing. The ongoing enhancements in the healthcare and research sectors in both countries are expected to sustain North America’s leading position in the methylene blue market.

Europe Analysis

Europe has rapidly emerged as the fastest-growing methylene blue market, driven by escalating demand from the pharmaceutical and biotechnology sectors. The UK and Germany, in particular, are at the forefront of this expansion. In the UK, methylene blue is extensively utilized in medical diagnostics and therapeutic applications, including the treatment of methemoglobinemia and as a vital staining agent in various laboratory procedures. Germany’s robust chemical and pharmaceutical industries further bolster the methylene blue market, with methylene blue playing a crucial role in biological research and healthcare applications.

Notably, companies such as Merck KGaA, headquartered in Darmstadt, Germany, are key players in this area. Merck offers high-purity methylene blue products tailored for medical and research purposes. The company’s methylene blue offerings are formulated to meet strict quality and safety standards, making them suitable for sensitive medical uses such as treating methemoglobinemia, as well as in cellular staining and microbiological studies. By maintaining rigorous manufacturing practices and investing heavily in research and development, Merck ensures that its methylene blue products are reliable, effective, and aligned with global regulatory requirements. This underscores the company's integral role in advancing scientific and medical endeavors within these nations.

Methylene Blue Market Share
Get more information on this report: Request Free Sample PDF

Companies Dominating the Methylene Blue Market

    Key players in the methylene blue market leverage advanced purification techniques, nanotechnology-based delivery systems, and sustainable manufacturing processes to ensure high purity, improved therapeutic efficacy, and reduced environmental impact. These innovations enhance application in medical, research, and industrial sectors, positioning them as a leader in a competitive and evolving methylene blue market.

    • HaiHang Industry
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Zibo Tianyuan Chemical
    • Jiangsu Chenhong Pharmaceutical
    • Jiangsu Changshu Qiming Group
    • Jiangsu Haohua Chemical
    • Songbaiwei Chemical
    • Shanghai Jucheng Chemical
    • Jiading Rongyu Chemical
    • Shandong Qilu Petrochemical
    • Guangdong Zhongshan Yiya Chemical
    • Qingdao Mingcheng Chemical
    • Union Blue
    • Zhejiang Rongqi Pharmaceutical
    • Yiyang Haishan

In the News

  • In March 2024, Alzforum highlighted ongoing research into methylene blue derivatives for the treatment of Alzheimer's disease. TauRx is analyzing specific subgroups to advocate once more for the use of a methylene blue derivative.
  • In December 2023, Zydus Lifesciences obtained final approval from the USFDA to produce and sell Methylene Blue Injection, a generic version of ProvayBlue Injection, available in 10mg/2ml and 50mg/5ml formulations.
  • In March 2025, Daiichi Sankyo introduced DATROWAY® in Japan, a therapy targeting TROP2, designed as a novel treatment option for patients with previously treated unresectable or recurrent HR-positive, HER2-negative breast cancer.
  • In December 2024, Daiichi Sankyo revealed the commencement of a Phase 3 clinical trial for VANFLYTA® targeting patients who have recently been diagnosed with FLT3-ITD negative acute myeloid leukemia (AML).

Author Credits:   Rajrani Baghel


  • Report ID: 7508
  • Published Date: Apr 15, 2025
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of methylene blue was over USD 400 million.

The market size for methylene blue is projected to cross USD 1 billion by the end of 2037, expanding at a CAGR of 7.6% during the forecast period, i.e., between 2025 and 2037.

The major players in the market are Zibo Tianyuan Chemical, Jiangsu Chenhong Pharmaceutical, Jiangsu Changshu Qiming Group, Jiangsu Haohua Chemical, Songbaiwei Chemical, Shanghai Jucheng Chemical , and others.

The healthcare segment is predicted to gain the largest market share of 44.6% during the projected period.

The North America’s methylene blue sector is poised to hold a 37.2% share by the end of 2037.
footer-bottom-logos
GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

See our insights in action - schedule your demo now!

Live Sample Reading